Summary: Evaluated bisoprolol versus placebo in systolic heart failure patients with New York Heart Association functional class III or IV symptoms. The primary endpoint of all-cause mortality was significantly reduced. All-cause hospitalizations and sudden cardiac death were also reduced.

Original Publication:

Lancet. 1999 Jan 2;353(9146):9-13.

Eponym: The Cardiac Insufficiency BIsoprolol Study II